Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma

Technology appraisal guidance
Reference number: TA396
Published: 22 June 2016

History

Final appraisal determination

Final appraisal determination
Final appraisal determination document (PDF 342 KB)

Published:

29 April 2016
Committee papers (PDF 10.71 MB)

Published:

29 April 2016

Consultation documents published: - scope consultation

Final scope (PDF 108 KB)

Published:

12 October 2015
Final matrix (PDF 101 KB)

Published:

12 October 2015
NICE's response to comments on the draft scope and provisional matrix (PDF 208 KB)

Published:

12 October 2015
Equality impact assessment (Scoping) (PDF 121 KB)

Published:

12 October 2015

Melanoma (BRAF V600E mutation positive, unresectable, metastatic) - dabrafenib and trametinib: draft scope (rescope)

Melanoma (BRAF V600E mutation positive, unresectable, metastatic) - dabrafenib and trametinib: draft scope (rescope) (PDF 114 KB)

Published:

21 August 2015

Melanoma (BRAF V600E mutation positive, unresectable, metastatic) - dabrafenib and trametinib: draft matrix (rescope)

Melanoma (BRAF V600E mutation positive, unresectable, metastatic) - dabrafenib and trametinib: draft matrix (rescope) (PDF 97 KB)

Published:

20 August 2015

Melanoma (BRAF V600E mutation positive, unresectable, metastatic) - dabrafenib and trametinib: draft scope

Melanoma (BRAF V600E mutation positive, unresectable, metastatic) - dabrafenib and trametinib: draft scope (PDF 107 KB)

Published:

25 September 2013

Melanoma (BRAF V600E mutation positive, unresectable, metastatic) - dabrafenib and trametinib: draft matrix

Melanoma (BRAF V600E mutation positive, unresectable, metastatic) - dabrafenib and trametinib: draft matrix (PDF 105 KB)

Published:

25 September 2013